EUVIMEDEUVIMED entdecken
Open Access

PEAKS activation by PROTAC EPIC-0726 potentiates temozolomide in glioblastoma via K63/K48 ubiquitination-dependent ERK/AKT suppression and p21 stabilization

Biao Hong, Dongyuan Su, Xiaoteng Cui, Jixing Zhao, Qixue Wang, Qi Zhan, Eryan Yang, Shixue Yang, Jiasheng Ju, Yanping Huang, Chunchao Cheng, Yaqing Ding und 7 weitere

Neuro-Oncology · 2026

DOI: 10.1093/neuonc/noaf253 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2026. Verfasst von Biao Hong und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Tianjin Medical University General Hospital, Laboratory of Neuro-oncology, Tianjin Neurological Institute, Tianjin, China…. Hauptthemen laut MEDLINE: Temozolomide, Glioblastoma, Brain Neoplasms, Cyclin-Dependent Kinase Inhibitor p21. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Noncommunicable Chronic Diseases, National Science and Technology Major Project, Tianjin Science and Technology Plan Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AbstractAbstract Background Despite advances in small-molecule inhibitors (SMIs), the clinical outcomes for glioblastoma (GBM) remain bleak. Recently, polymerase I and transcript release factor (PTRF/Cavin1) has emerged as a promising therapeutic target, with its inhibitor EPIC-1042 demonstrating preclinical antitumor activity. However, the therapeutic limitations of SMIs necessitate alternative strategies to achieve enduring target suppression.

Methods

EPIC-0726, a proteolysis-targeting chimera (PROTAC) degrader of PTRF, was developed through computer-aided drug design (CADD). Target engagement and degradation specificity were validated by Western blot. Quantitative proteomics identified downstream effectors, while mechanistic insights were elucidated through co-immunoprecipitation, immunofluorescence, and ubiquitination profiling. Orthotopic GBM models were used to assess therapeutic efficacy and temozolomide (TMZ) sensitization.

Results

EPIC-0726 induced dose-dependent PTRF degradation via the ubiquitin-proteasome system (UPS), requiring ternary complex formation. Proteomic analysis revealed RBX1, a core component of E3 ligase complexes, as a key downstream target. PTRF degradation by EPIC-0726 destabilized RBX1, concurrently suppressing K63-linked ubiquitination-mediated ERK1/2/AKT activation and stabilizing p21 via impaired K48-dependent proteasomal degradation. In vivo, EPIC-0726 monotherapy inhibited GBM growth and synergized with TMZ, with effects more potent than that of EPIC-1042.

Conclusion

This study establishes PROTAC-mediated PTRF degradation as a mechanistically distinct manner to activate proteolysis strategy-enhanced TMZ efficacy by ERK1/2/AKT kinase suppression and p21 stabilization (PEAKS) through the PTRF-RBX1 regulatory axis. The superior efficacy of EPIC-0726 over EPIC-1042, particularly in overcoming TMZ resistance, provides a paradigm-shifting therapeutic approach for GBM. Our findings warrant the clinical translation of EPIC-0726 as both a monotherapy and a backbone for combination regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomideGlioblastomaBrain NeoplasmsCyclin-Dependent Kinase Inhibitor p21HumansAnimalsUbiquitinationMiceXenograft Model Antitumor AssaysProto-Oncogene Proteins c-aktAntineoplastic Agents, AlkylatingMice, NudeTumor Cells, CulturedCell ProliferationDrug SynergismProteolysisApoptosis

Stichwörter der Autor:innen

PEAKSPROTACPTRF-RBX1 axisTMZ efficacypolyubiquitination modification

Substanzen

TemozolomideProto-Oncogene Proteins c-aktCyclin-Dependent Kinase Inhibitor p21Antineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Department of Neurosurgery, Tianjin Medical University General Hospital, Laboratory of Neuro-oncology, Tianjin Neurological Institute, Tianjin, China (B.H., D.S, X.C., Q.W., Q.Z., J.J., Y.H., C.C., Y.D., H.X., L.C., Y.Z…
  • Key Laboratory of Post-Neuro Injury Neuro-Repair and Regeneration in Central Nervous System, Ministry of Education and Tianjin City, Tianjin, China (B.H., D.S, X.C., Q.W., Q.Z., J.J., Y.H., C.C., Y.D., H.X., L.C., Y.Z.,…
  • Department of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine and Institute of Brain and Brain-Inspired Science, Shandong University, Jinan, Shandong, China (J.Z.).
  • Department of Gynecology and Obstetrics, Tianjin Key Laboratory of Female Reproductive Health and Eugenics, Tianjin Medical University General Hospital, Tianjin, China (E.Y.).
  • Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, China (S.Y.).

ORCID-Profile: Chunsheng Kang

Förderung

  • Noncommunicable Chronic Diseases
  • National Science and Technology Major Project
  • Tianjin Science and Technology Plan Project
  • National Key R&D Program of China

Zitieren

APA

Hong, B., Su, D., Cui, X., Zhao, J., Wang, Q., Zhan, Q., Yang, E., Yang, S., Ju, J., Huang, Y., Cheng, C., Ding, Y., Xu, H., Cui, L., Zhao, Y., Zhao, X., Liang, S., Liu, Y., & Kang, C. (2026). PEAKS activation by PROTAC EPIC-0726 potentiates temozolomide in glioblastoma via K63/K48 ubiquitination-dependent ERK/AKT suppression and p21 stabilization. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf253

Vancouver

Hong B, Su D, Cui X, Zhao J, Wang Q, Zhan Q, et al. PEAKS activation by PROTAC EPIC-0726 potentiates temozolomide in glioblastoma via K63/K48 ubiquitination-dependent ERK/AKT suppression and p21 stabilization. Neuro-Oncology. 2026. doi:10.1093/neuonc/noaf253

BibTeX
@article{Hong2026,
  author = {Hong, Biao and Su, Dongyuan and Cui, Xiaoteng and Zhao, Jixing and Wang, Qixue and Zhan, Qi and Yang, Eryan and Yang, Shixue and Ju, Jiasheng and Huang, Yanping and Cheng, Chunchao and Ding, Yaqing and Xu, Hanyi and Cui, Longtao and Zhao, Yilin and Zhao, Xun and Liang, Siwen and Liu, Yuhao and Kang, Chunsheng},
  title = {PEAKS activation by PROTAC EPIC-0726 potentiates temozolomide in glioblastoma via K63/K48 ubiquitination-dependent ERK/AKT suppression and p21 stabilization},
  journal = {Neuro-Oncology},
  year = {2026},
  doi = {10.1093/neuonc/noaf253}
}
Kostenlos starten →